Abstract
Purpose To retrospectively evaluate in patients with non-arteritic ischaemic optic neuropathy (NAION) whether aspirin reduces the frequency of second eye involvement.
Methods In 52 patients who presented with NAION between 1984 and 1997 adequate information was available regarding use of aspirin, presence of risk factors and second eye involvement.
Results Second eye involvement was noted in 8 of 16 patients (50%) who did not receive aspirin, in 3 of 8 patients (38%) who received 100 mg/day aspirin and in only 5 of 28 patients (18%) who received aspirin 325 mg/day. Moreover, mean time to second eye involvement was 63 months in patients who did not receive aspirin versus 156 months in patients who received aspirin 325 mg/day.
Conclusion Our results strongly suggest that aspirin at 325 mg/day may be effective in reducing the frequency of second eye involvement with NAION.
Similar content being viewed by others
Article PDF
References
Hayreh SS . Anterior ischaemic optic neuropathy. Br J Ophthalmol 1974;58:955–63.
Hayreh SS . The optic nerve head circulation in health and disease. Exp Eye Res 1995;61:259–72.
Johnson LN, Arnold AC . Incidence of nonarteritic and arteritic anterior ischaemic optic neuropathy: population-based study in the state of Missouri and Los-Angeles county, California. J Neuroophthalmol 1994;14:38–44.
Repka MX, Savino PJ, Schatz NJ, Sergott RC . Clinical profile and long term implications of anterior ischaemic optic neuropathy. Am J Ophthalmol 1983;96:478–83.
Moro F, Doro D, Mantovani E . Anterior ischaemic optic neuropathy and aging. Metab Pediatric Syst Ophthalmol 1989;12:46–57.
Hayreh SS, Joos KM, Podhajsky P, Long CR . Systemic diseases associated with nonarteritic anterior ischaemic optic neuropathy. Am J Ophthalmol 1994;118:766–80.
Jacobson DM, Vierkant RA, Belongia EA . Nonarteritic anterior ischaemic optic neuropathy: a case-control study of potential risk factors. Arch Ophthalmol 1997;115:1403–7.
Salomon O, Huna-Baron R, Kurtz S, Steinberg DM, Moisseiev J, Rosenberg N, et al. Analysis of vascular and prothrombotic risk factors in patients with nonarteritic anterior ischaemic optic neuropathy (NAION). Ophthalmology 1999;106:739–42.
Ellenberger C, Keltner JL, Burde RM . Acute optic neuropathy in older patients. Arch Neurol 1973;28:182–5.
Kupersmith MJ, Frohman L, Sanderson M, Jacobs J, Hirschfeld J, Ku C, et al. Aspirin reduces the incidence of second eye NAION: a retrospective study. J Neuroophthalmol 1997;17:250–3.
Beck RW, Hayreh SS, Podhajsky PA, Tan ES, Moke PS . Aspirin therapy in nonarteritic anterior ischaemic optic neuropathy. Am J Ophthalmol 1997;123:212–7.
The Salt Collaborative Group. Swedish aspirin low dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345–9.
Barnett HJ, Eliasziw M, Meldrum HE . Drugs and surgery in the prevention of ischaemic stroke. N Engl J Med 1995;332:4:238–48.
UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial interim results. BMJ 1988;296:316–20.
Santos MT, Valles J, Aznar J, Marcus AJ, Broekman MJ, Safier LB . Prothrombotic effects of erythrocytes on platelet reactivity: reduction by aspirin. Circulation 1997;95:63–8.
Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality; the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350–5.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Salomon, O., Huna-Baron, R., Steinberg, D. et al. Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye 13, 357–359 (1999). https://doi.org/10.1038/eye.1999.90
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/eye.1999.90
Keywords
This article is cited by
-
Nichtarteriitische anteriore ischämische Optikusneuropathie (nAION)
Die Ophthalmologie (2023)
-
Bilateral NAION and GPIbα gene
BMC Ophthalmology (2019)
-
Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy
Eye (2015)
-
Lipoprotein(a) als wichtiger Risikofaktor für Gefäßverschlüsse. Bericht über eine beidseitige nicht-entzündliche anteriore ischämische Optikusneuropathie mit erfolgreicher Behandlung eines Auges und Langzeitbeobachtung
Spektrum der Augenheilkunde (2014)
-
Nonarteritic Anterior Ischemic Optic Neuropathy
Current Treatment Options in Neurology (2011)